Stock RHO5 ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roche Holding AG Börse Stuttgart

Equities

RHO5

CH0012032048

Delayed Börse Stuttgart
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Roche Holding AG -1.36% +15.08%
06-28 Swiss Market Index Closes Little Changed Amid Key European Inflation Data MT
06-28 Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication MT

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.

Weaknesses

  • The company's enterprise value to sales, at 3.51 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROCHE HOLDING AG Stock Roche Holding AG
+15.08% 224B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
B+
NOVARTIS AG Stock Novartis AG
+13.31% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RHO5 Stock
  5. Ratings Roche Holding AG